According to distribution characteristics of TGFβ in vivo and the penetration of TGFβ-targeted carrier drugs into solid tumors (1, 31, 37), radionuclides such as 18F and 68Ga can be used to label TGFβ-targeted small molecules or peptides, for research and application development of diagnostic drugs, and the potential indications may include but not be limited to hematological malignancies, sarcomas, pancreatic adenocarcinoma, and lung squamous cell carcinoma. This evidence concerns the gene TGFB1 and hematologic disorder.